Medtronic touts ‘closed-loop’ insulin management system In its latest step on the quest to create an artificial pancreas, Medtronic (NYSE:MDT) said a pivotal trial showed that its hybrid “closed-loop” insulin management system proved safe and effective. The HCL system is designed to automatically control blood glucose levels with minimal input or supervision from patients or […]
Insulet (NSDQ:PODD) said yesterday that it’s launching a new data system for its OmniPod device that uses Glooko‘s diabetes management platform. Medtronic (NYSE:MDT)-backed Glooko’s platform is designed to integrate data from blood glucose monitors and other devices with either an Apple (NSDQ:AAPL) iPhone or Google (NSDQ:GOOG) Android application. Food intake, medication and insulin dosage can also be recorded to provide context for changes in […]
Medtronic (NYSE:MDT) today announced a slew of developments from its diabetes treatment arm, including FDA clearance of its MiniMed Connect diabetes monitoring system; a partnership with Samsung Electronics (LON:BC94) to develop technology for diabetes management; and an agreement with diabetes-monitoring platform developer Glooko. The announcements were made at the American Diabetes Assn.’s annual meeting in Boston. […]
Glooko said yesterday that it inked deals with Dexcom (NSDQ:DXCM) and Insulet (NSDQ:PODD) to supply device data from both companies to its diabetes management platform. Glooko’s platform will now integrate Dexcom’s continuous glucose monitoring systems and Insulet’s OmniPod insulin management systems in a new version of the platform that’s slated for a summer release, the Palo Alto, Calif.-based company […]
March 17, 2015 by Brad Perriello
California diabetes management company Glooko Inc. this month unveiled its new Population Tracker, offering health systems patient monitoring that aims to keep track of at-risk patients and reduce hospitalizations.
Glooko continues to carve out a niche in the mobile diabetes management space.
Silicon Valley mHealth company Glooko is expanding its FDA-approved mobile diabetes management system to include an app for the Android operating system.
Palo Alto, Calif.-based Glooko received 510(k) clearance from the FDA for the Android app and a new cable to connect to glucose monitors, a move company officials say will help it expand internationally.
Silicon Valley mHealth company Glooko is rocketing forward in the mobile diabetes management space since its inception less than 3 years ago, boasting multiple FDA clearances, wide-ranging industry partnerships and a growing base of patient users and healthcare provider subscribers.
Just last month, Glooko won FDA clearance for the 2nd generation of its iPhone diabetes management app and launched the 1st subscriber portal at San Diego’s Scripps Whittier Diabetes Institute.